Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Lotfi Benboubker
Daratumumab-Based Regimens Are Highly Effective and Well Tolerated in Relapsed or Refractory Multiple Myeloma Regardless of Patient Age: Subgroup Analysis of the Phase 3 CASTOR and POLLUX Studies
Haematologica
Hematology
Related publications
Daratumumab, Lenalidomide, and Dexamethasone (Drd) vs Lenalidomide and Dexamethasone (Rd) in Relapsed or Refractory Multiple Myeloma (Rrmm): Efficacy and Safety Update (Pollux)
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Once- Versus Twice-Weekly Carfilzomib in Relapsed and Refractory Multiple Myeloma by Select Patient Characteristics: Phase 3 A.R.R.O.W. Study Subgroup Analysis
Blood Cancer Journal
Oncology
Hematology
Daratumumab, Bortezomib and Dexamethasone (Dvd) vs Bortezomib and Dexamethasone (Vd) in Relapsed or Refractory Multiple Myeloma (Rrmm): Efficacy and Safety Update (Castor)
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Cost-Effectiveness Analysis of Daratumumab, Lenalidomide, and Dexamethasone (DRD) and Daratumumab, Bortezomib, and Dexamethasone (DVD) Versus Standard of Care in Relapsed or Refractory Multiple Myeloma (RRMM)
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Daratumumab vs. Pomalidomide for the Treatment of Relapsed/Refractory Multiple Myeloma: A Cost‐effectiveness Analysis
American Journal of Hematology
Hematology
Blood Transfusion Management and Transfusion-Related Outcomes in Daratumumab-Treated Patients With Relapsed or Refractory Multiple Myeloma
Clinical Lymphoma, Myeloma and Leukemia
Cancer Research
Oncology
Hematology
Carfilzomib for Relapsed or Refractory Multiple Myeloma
The Lancet Oncology
Oncology
Results of an Early Access Treatment Protocol of Daratumumab in United States Patients With Relapsed or Refractory Multiple Myeloma
Cancer
Cancer Research
Oncology
Lenalidomide Plus Dexamethasone Is More Effective Than Dexamethasone Alone in Patients With Relapsed or Refractory Multiple Myeloma Regardless of Prior Thalidomide Exposure
Blood
Biochemistry
Immunology
Cell Biology
Hematology